Jupiter Life Line Hospitals Limited is a multi-specialty tertiary and quaternary healthcare provider incorporated in 2007, primarily serving the Mumbai Metropolitan Area (MMR) and western region of India. The company has a market capitalization of ₹9,547 Crore as of June 27, 2025. Led by founding Promoter Dr. Ajay Thakker, the company commenced its business operations in December 2002.
The healthcare provider operates under the Jupiter brand and has established itself as a prominent player in the western Indian healthcare sector. The company is engaged in providing services in the field of healthcare and related services, with a total bed capacity of approximately 1,194 hospital beds across three hospitals.
Jupiter Life Line Hospitals operates three hospitals under the Jupiter brand in Thane, Pune, and Indore, with an operational bed capacity of 950 beds and 900 beds, and over 1,246 doctors, including specialists, physicians, and surgeons. The company's hospital portfolio demonstrates strong operational metrics across its facilities.
- The Thane hospital, operational since 2007, serves as the flagship facility with 377 beds, average occupancy rate of 72.0%, and ARPOB (Average Revenue Per Occupied Bed) of ₹66,700.
- The Pune hospital, operational since 2017, has 375 beds, average occupancy rate of 67.0%, and ARPOB of ₹55,000.
- The Indore hospital, operational since 2020, operates with 231 beds, average occupancy rate of 59.0%, and ARPOB of ₹44,700.
Jupiter Life Line Hospitals is actively expanding its network to enhance its presence in western India. The company added 22 beds in Pune in Q2 FY25, with 75 additional beds under development at the Indore hospital, expected by Q4 FY25. Construction of the Dombivli hospital is on track, and regulatory approvals are being finalized for a second unit in Pune. These expansions will raise the total bed capacity to approximately 2,500 beds.
The company now has visibility into a 2,500-bed network in its target region of Western India, with the 500-bed Dombivli hospital expected to launch as planned in Q1 FY27. The second Pune hospital, also with 500 beds, has received all building permissions and environmental clearances, with excavation work commenced and construction expected to begin after the monsoon.
For full year 2025, consolidated revenue from operations increased 17.5% to ₹1,245.4 Crore in FY25 against ₹1,059.8 Crore in FY24. EBITDA increased 22.5% to ₹296.6 Crore in FY25 against ₹242.1 Crore in FY24. PAT increased 9.6% to ₹193.5 Crore in FY25 against ₹176.6 Crore in FY24.
For Q4 FY25, consolidated revenue from operations increased 12.1% to ₹323.1 Crore against ₹288.2 Crore in Q4 FY24. EBITDA increased 23.9% to ₹78.3 Crore in Q4 FY25, while PAT dropped 0.9% to ₹44.9 Crore in Q4 FY25 against ₹45.3 Crore in Q4 FY24.
Jupiter Life Line Hospitals operates multi-specialty hospitals in India, offering over 30 specialty treatments and promoting medical tourism. According to the CRISIL Report, the company's Thane and Indore hospitals are amongst the few hospitals in the western region of India to provide neuro-rehabilitation services through a dedicated robotic and computer-assisted neuro-rehabilitation center.
The company has achieved significant medical milestones including organ transplant capabilities, with the company carrying out small bowel intestine transplant surgery at Thane Hospital in 2021 and heart transplant surgery at Thane Hospital in 2022.
The chairman of the company is Ajay Thakker, and the managing director is Ajay Thakker. The Board of Jupiter Life Line Hospitals appointed Dr. Ankit Thakker as Joint Managing Director and Chief Executive Officer of the Company for a period of five years with effect from July 11, 2025, till July 10, 2030.
Jupiter Life Line Hospitals Ltd has given a return of 17.09% in the last 1 year. The company's 52-week high share price is ₹1,759.00 and 52-week low share price is ₹1,177.05. Promoter holding in Jupiter Life Line Hospitals Ltd has remained stable at 40.91% as of March 2025.
The company is strategically expanding its hospital network in western India, with new facilities planned in Dombivli and Pune, aimed at enhancing operational capacity and addressing clinical challenges. Prabhudas Lilladher maintains a 'BUY' rating for Jupiter Life Line Hospitals, setting a target price of ₹1,720. The company shows strong operational efficiency and growth potential, with a projected 20% CAGR in EBITDA over FY25-27E.
The healthcare provider continues to focus on operational excellence while maintaining its position as a leading multi-specialty hospital chain in western India, with clear expansion plans to nearly double its bed capacity over the next few years.
